Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€43.92

€43.92

-1.740%
-0.78
-1.740%
€61.40

€61.40

 
19.09.24 / Tradegate WKN: 850501 / Symbol: BMY / Name: Bristol-Myers / Stock / Pharmaceuticals / Large Cap /
Latest predictions
€55.50
06.09.24
-2.38%
buy
€37.80
22.08.24
2.34%
€61.40
27.12.23
-2.51%
buy
23.12.23
-3.44%
buy
€65.03
30.10.23
-5.54%
buy
€47.31
27.10.23
-8.48%
Your prediction

Bristol-Myers Squibb Stock

We can see a decrease in the price for Bristol-Myers Squibb. Compared to yesterday it has lost -€0.780 (-1.740%).
Currently there is a rather positive sentiment for Bristol-Myers Squibb with 6 Buy predictions and 3 Sell predictions.
As a result the target price of 61 € shows a positive potential of 38.89% compared to the current price of 43.92 € for Bristol-Myers Squibb.
For the coming years our community has positive and negative things to say abot the Bristol-Myers Squibb stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Business model" there were negative voices in the community.

Pros and Cons of Bristol-Myers Squibb in the next few years

Pros
?
C******** o* t** e**********
?
M***** P*******
?
B****
Cons
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Bristol-Myers Squibb vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Bristol-Myers Squibb -1.740% 0.780% -1.248% -20.000% -5.345% -15.991% -3.121%
Johnson & Johnson -1.200% -0.713% 2.570% -2.778% 4.294% 5.170% 25.429%
Elanco Animal Health Inc. -1.330% 2.475% 1.048% 21.604% -0.163% -51.147% -
Biogen Inc. 1.070% 0.979% -2.932% -24.938% -23.473% -29.470% -15.421%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2024-08-01

When evaluating the financials of Bristol-Myers Squibb Company (symbol: BMY), the impression is that the company embodies a complex but compelling pharmaceutical player characterized by both strengths and challenges. While the balance sheets, cash flow statements, and income statements showcase a robust revenue-generating ability, several underlying factors such as profitability ratios and market performance warrant further scrutiny.

In order to provide clarity on Bristol-Myers’ financial health, it is necessary to explore the various pros and cons that define its current financial position.

*Pros: *

Comments

Prediction Sell
Perf. (%) 2.34%
Target price 37.800
Change
Ends at 22.08.25

Bristol-Myers Squibb (NYSE: BMY) had its price target raised by analysts at Barclays PLC from $41.00 to $42.00. They now have an "underweight" rating on the stock.
Ratings data for BMY provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -2.51%
Target price 61.404
Change
Ends at 27.12.24

Bristol-Myers Squibb (NYSE: BMY) had its price target lowered by analysts at Bank of America Co. from $72.00 to $68.00. They now have a "buy" rating on the stock.
Ratings data for BMY provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -5.54%
Target price 65.026
Change
Ends at 30.10.24

Bristol-Myers Squibb (NYSE: BMY) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $81.00 to $69.00. They now have a "buy" rating on the stock.
Ratings data for BMY provided by MarketBeat
Show more